Authors' objectives:

This study aims to assess the effectiveness of tesaglitazar for type 2 diabetes and associated lipid abnormalities.

Authors' recommendations: Tesaglitazar (Galida, AZ242) is an oral, dual (alpha- plus gamma-) peroxisome proliferator-activated receptor (PPAR) agonist in phase III clinical trials as an alternative to existing treatments for type 2 diabetes and associated lipid abnormalities. Available data is very limited, but in a phase II trial in 390 non-diabetic patients with manifestations of insulin-resistance, tesaglitazar was well tolerated and showed significant and dose-dependent improvements in lipid and glucose metabolism and insulin sensitivity compared with placebo. There are three phase III monotherapy trials of tesaglitazar ongoing versus sulphonylurea, metformin and pioglitazone, and combination trials of tesaglitazar and metformin versus metformin alone, and tesaglitazar and sulphonylurea versus sulphonylurea alone.

Authors' methods: Overview

Project Status: Completed

Year Published: 2005

URL for published report: http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: National Horizon Scanning Centre (NHSC)